106 results about "Mouse Fibroblast" patented technology

This disclosure provides an improved system for culturing human pluripotent stem cells. Traditionally, pluripotent stem cells are cultured on a layer of mouse embryonic fibroblast feeder cells to prevent them from differentiating. In the system described here, the role of feeder cells is replaced by defined components added to the culture environment that support rapid proliferation without differentiation. The medium contains an isotonic buffer, a blend of essential nutrients such as protein and lipids, and an effective growth factor or combination of factors that promote proliferation while inhibiting differentiation. Culturing human embryonic stem cells in fresh medium on an extracellular matrix according to this invention causes the cells to expand surprisingly rapidly, while retaining the ability to differentiate into cells representing all three embryonic germ layers. This new culture system allows for bulk proliferation of pPS cells for commercial production of important products for use in drug screening and human therapy.

We have made retrovirus particles displaying a functional antibody fragment. We fused the gene encoding an antibody fragment directed against a hapten with that encoding the viral envelope protein (Pr80env) of the ecotropic Moloney murine leukemia virus. The fusion gene was co-expressed in ecotropic retroviral packaging cells with a retroviral plasmid carrying the neomycin phosphotransferase gene (neo), and retroviral particles with specific hapten biding activities were recovered. Furthermore the hapten-binding particles were able to transfer the neo gene and the antibody-envelope fusion gene to mouse fibroblasts. In principle, the display of antibody fragments on the surface of recombinant retroviral particles could be used to target virus to cells for gene delivery, or to retain the virus in target tissues, or for the construction of libraries of viral display packages.

The invention discloses an inducing method for directionally differentiating human embryonic stem cells to corneal endothelial cells. The method comprises the steps of: cultivating the human embryonic stem cells on a mouse embryonic fibroblast feed layer; sorting human embryonic stem cell clone groups in good state; grafting the groups on a human corneal stromal fibroblast layer processed by mitomycin C and cultivating for 7 days, wherein the human embryonic stem cells are differentiated to rosettes; separating and transferring the rosettes from the human corneal stromal fibroblast layer to a culture bottle; cultivating continuously for 7 days by using a neural crest stem cell culture medium; sorting the neural crest stem cells by a flow cytometry; adding the neural crest stem cells into the culture bottle; placing in a 5% CO2 incubator for incubating and cultivating at 37 DEG C by using a human corneal endothelial cell culture medium; changing the liquid every other day; and cultivating for about 10 days to obtain the corneal endothelial cells. The multiplication capacity of the corneal endothelial cells are similar to that of human corneal endothelial cells and the corneal endothelial cells can be transferred to 1-2 generations in vitro maximally. The corneal endothelial cells can be used as seed cells for cornea construction and transplant in tissue engineering.

The invention relates to a polyurethane material with protein adsorption resistance and cell adhesion resistance and a preparing method thereof. The material comprises a substrate and a modification layer. The substrate is made of polyurethane. The modification layer is obtained by polymerizing a vinyl pyrrolidone monomer on the surface of the substrate by utilization of an atom transfer radical polymerization technology. The material is prepared by steps of: subjecting the polyurethane to isocyanic acid esterification, performing amination, fixing a bromine initiator, and initiating graft polymerization of the vinyl pyrrolidone on the surface of the material. The surface of the polyurethane material prepared by the method has good hydrophilicity, good resistance to bovine serum fibrinogen adsorption, bovine serum albumin adsorption and lysozyme adsorption, and a function of resisting cell adhesion of mouse fibroblast cells (L-929), so that the polyurethane material is suitable for preparing biomedical catheter materials with complex shape structures.

This disclosure provides an improved system for culturing human pluripotent stem cells. Traditionally, pluripotent stem cells are cultured on a layer of feeder cells (such as mouse embryonic fibroblasts) to prevent them from differentiating. In the system described here, the role of feeder cells is replaced by components added to the culture environment that support rapid proliferation without differentiation. Effective features are a suitable support structure for the cells, and an effective medium that can be added fresh to the culture without being preconditioned by another cell type. Culturing human embryonic stem cells in fresh medium according to this invention causes the cells to expand surprisingly rapidly, while retaining the ability to differentiate into cells representing all three embryonic germ layers. This new culture system allows for bulk proliferation of pPS cells for commercial production of important products for use in drug screening and human therapy.

The invention discloses a preparation method of a chitosan/polyvinyl alcohol sponge dressing containing nano-silver. The invention relates to an antibacterial dressing for therapy of trauma, and the chitosan/polyvinyl alcohol sponge dressing containing the nano-silver is prepared by adding nano-silver/polyvinyl alcohol solution and polyvinyl alcohol/chitosan blend solution. The obtained dressing has good biocompatibility and hemostatic and antibacterial effects, and can promote the wound healing; the product can accelerate the wound healing, release nano-silver particles in a sustained manner, be acted on regenerated bacteria constantly, have the lasting and high-efficient sterilization characteristics and avoid the drug resistance during the wound treatment process; the research on the toxic effect of the material to mouse fibroblasts shows that the product has no obvious toxicity to the cells and has the effect of promoting the growth of the cells; and preparation method has simple process equipment and low price of experimental raw materials and is conductive to industrialization.

The invention discloses a preparation method of chitosan/ acetalized poval medical dressing, and in particular relates to a preparation technology of poval sponge. A dressing with bioactivity can be prepared by adding a poval/ chitosan mixed solution in poval acetalation reaction. The chitosan/acetalized poval medical dressing has biocompatibility,the effects of inflammation, blood stopping, wound surface healing promotion, good breathability, water absorbability and tensile strength; in addition, proved by the search on toxic effect on mouse fibroblast cells, the chitosan/acetalized poval medical dressing has no obvious toxicity to the mouse fibroblast cells, but has the effect of promoting the growth of the mouse fibroblast cells.

The invention provides a method for culturing human induced pluripotent stem cells (iPSCs) by using human bone marrow mesenchymal stem cells as a trophoblast. The method comprises the following steps of: obtaining the human iPSCs from child foreskin fibroblasts by using third to fifth generation human bone marrow mesenchymal stem cells obtained through subculture and culture after thawing from low-temperature freezing, performing amplification culture, and inoculating into trophoblast cells to obtain the human iPSCs. In the method, the human iPSCs are cultured by using the human bone marrow mesenchymal stem cells as the trophoblast cells instead of mouse embryonic fibroblasts in the conventional method, so that the pollution of heterologous cells in a culture system is reduced, that the culture system can make the human iPSCs amplified in vitro is proved, biological characteristics and multipotency of the human iPSCs are maintained for a long time, and the possibility of clinical application of the human iPSCs is provided.

This invention uses mesoporous silica nanoparticles and other nanostructured materials to formulate polyacrylate-based bone cement for achieving an enhanced and controlled elution of active ingredients such as antibiotics. This invention overcomes the limitation of low antibiotic release from commercial polyacrylate-based bone cements using for example, PMMA. In certain aspects, the formulation enables a sustained release of antibiotics from the bone cement over a period of 80 days and achieves 70% of total drug release, whereas the commercial antibiotic bone cement (e.g., SmartSet GHV) only releases about 5% of the antibiotics on the first day and subsequently an almost negligible amount. In addition, the mechanical properties of our formulated bone cements are well retained. The inventive bone cement exhibits good antibacterial properties and has very low cytotoxicity to mouse fibroblast cells.

The present invention relates to the field of traditional Chinese medicines, natural medicines and daily chemicals, particularly to a new Periplaneta Americana polypeptide capable of promoting tissue repair, and applications thereof, wherein the new polypeptide capable of promoting tissue repair is named Periplapeptide B, has a structure represented by a formula I, can promote the proliferation of mouse embryonic fibroblasts and the migration of human immortalized epidermal cells at a low concentration, has advantages of low toxic-side effect and good application prospect, and can be used for preparing drugs for treatment of trauma, scald and ulcer, or cosmetics for improving skin beauty, and daily chemicals. The formula I is H-Ala-Ala-Pro-Pro-Ser-Asn-Leu-Lys-Glu-Val-Pro-Ile-Ile-Ala-Tyr-OH.

The invention provides a sulfonic quantum dot/silk fibroin composite nanofiber membrane and a preparation method and application thereof. The preparation method comprises the following steps that degumming treatment is performed on natural silk, and silk fibroin is obtained; then, fibroin is dissolved in a lithium bromide water solution, and a silk fibroin sponge is obtained through dialysis, centrifugal and freeze drying; the silk fibroin sponge is dissolved into formic acid to be mixed to be uniform, then, a sulfonate graphene quantum dot water solution is ultrasonically and uniformly dispersed into a silk fibroin-formic acid solution, and a composite nanofiber membrane is prepared through electrostatic spinning equipment; mouse fibroblasts are used for performing cell viability evaluation on the composite nanometer member, and it shows that the composite nanometer membrane has the excellent biocompatibility. The prepared composite fiber membrane has the good biocompatibility and degradability, has the potential for promoting proliferation and differentiation of human bone marrow storm stem cells, and has the good biologic medical material application prospect.

The invention discloses a method for inducing mouse fibroblasts into cartilage by adopting a small-molecule composition. The method comprises the following steps: carrying out adherent culture on mouse embryo fibroblasts, removing a culture medium, slowly adding a chemical induction culture medium containing the small-molecule composition, carrying out culturing in the environment having the temperature of 37 DEG C and containing 3-8% of oxygen, 3-8 % of carbon dioxide and the balance of nitrogen, wherein the chemical induction culture medium containing the small-molecule composition is replaced every 2-3 days; carrying out continuous culturing for 4-12 days, thus obtaining intermediate state cells, wherein the small-molecule composition comprises an HDAC inhibitor, a GSK-3 inhibitor and aTGF-beta signal channel inhibitor; and transferring the intermediate state cells to a cartilage inducing medium, carrying out culturing in the environment having the temperature of 37 DEG C and containing 15-25% of oxygen, 3-8 % of carbon dioxide and the balance of nitrogen, wherein the cartilage inducing medium is replaced by the fresh cartilage inducing medium once every 3-4 days, and carryingout culturing for 14-28 days, thus obtaining a cartilage cell cluster. With the method provided by the invention, the problem that in the traditional methods, the fibroblasts can be induced to form cartilage cells through transdifferentiation only after an exogenous gene is introduced is solved, and the method provided by the invention is expected to be used for further solving the problem that seed cells of cartilage cells are in shortage or in-situ focus fibrosis exists.

The invention relates to a method for preparing an amniotic compound corneal limbus stem cell membrane, which comprises the following steps of: firstly, preparing a sterile amniotic membrane with epithelium removed, placing the epithelial surface of the amniotic membrane downwards on an end face of a sleeve made of a poly propylene material, and covering an embedded culture transwell on the amniotic membrane of the sleeve to obtain an amniotic-membrane-embedded culture mold; placing the culture mold in holes in a 6-hole plate on which a mouse embryonic fibroblast cell feeder layer is spread; and finally, preparing a corneal limbus stem cell suspension by using a digestion method, inoculating the suspension on the epithelial surface of the amniotic membrane, inoculating 2.0-3.0*10<5> corneal limbus stem cells for each culture mold, and culturing the corneal limbus stem cells for 10 days to obtain the amniotic compound corneal limbus stem cell membrane. Compared with the traditional amniotic membrane spreading method and the latex ring amniotic membrane fixing method, the amniotic compound corneal limbus stem cell membrane prepared with the method has flat amniotic membrane culturing surface and uniform corneal limbus stem cell stratified layer and especially has the advantage of convenience for clinic application and difficulty in rapture of the amniotic membrane.

The invention discloses a mouse fibroblast and an application thereof, and belongs to the field of cell biology. The cell is named mouse fibroblast MFC/HL-041 with the preservation number of CCTCC NO:C201714. The mouse fibroblast treated by mitomycin C or irradiated by radioactive rays is used for separation and subculture of normal primary epithelial cells and primary tumor cells. Obtained humanpulmonary normal primary epithelial cells and lung cancer primary epithelial cells are fresh and live in state, tight in arrangement, clear in cell boundary, high in stereoscopic impression and polygonal when examined under a microscope. The mouse fibroblast can be used for physiological study of human or animal normal cells, a virus infection model of in-vitro normal cells, drug sensitivity tests of the in-vitro normal cells for different drugs, drug screening for individualized treatment of cancer patients as well as research and development of new anti-cancer drugs.

The invention discloses a method for transfecting bovine somatic cells into inducted pluripotent stem cells (iPSCs) by adopting transcription factors, concretely comprising the following steps: 1) isolation and culture of bovine dermal fibroblasts; 2) cloning of bovine transcription factor genes maintaining pluripotency and construction of retroviral vectors of the transcription factor genes; 3) retrovirus packaging and preparation; and 4) infection of bovine dermal fibroblasts by retrovirus and acquisition of bovine inducted pluripotent stem cells. The invention first adopts the acellular human amniotic membranes as support to replace the mouse embryonic fibroblasts (MEFs) to maintain in vitro proliferation of the bovine iPSCs and keep the bovine iPSCs in undifferentiated pluripotent states for long time. The method which adopts gene inducing to generate the PSCs not only solves the technical problem that the PSCs of the animals such as cattle, sheep, pigs and other livestock are difficult to obtain but also avoids the problem of heterogeneous animal cell pollution caused by the feeder layer which applies the MEFs as the stem cells.

The invention discloses medical applications of four buxus alkaloids compounds in the preparation of antitumor medicines. Experiment results show that the four compounds KBA01, KBA02, KBA03 and KBR18, under the condition of concentration without toxicity to wild normal mouse embryonic fibroblast cells, can selectively kill mouse tumor cells with tumor specific mutant genes p53 and Ras; accordingly, the compounds are very strong in killing activity to human colon cancer cell strains with p53 mutants, but not strong in killing activity to human wild colon cancer cell strains with p53 mutants; and as shown in a GFP (Green Fluorescence Protein) reporter vector screening system of a gene promoter, the compounds KBA02 and KBA03 can activate a promoter of a cancer suppressor gene p16. The characteristics indicate that the compounds from the four buxus plant origins have application potentials for preparing personalized treatment medicines aiming at the tumor mutant genes p53 and Ras as well as the cancer suppressor gene p16.

The present invention discloses a method for preparing induced pluripotent stem cells by using a Xist Tale inhibitory transcription factor. Synergism of the transcriptional activator-like effectors (Tale)-based inhibitory transcription factor combined to a first intron region of Xist, Oct4, Sox2, Klf4 and c-Myc enhances the efficiency of induction of mouse fibroblasts to the induced pluripotent stem cells. Obtained iPSCs have typical pluripotent stem cell characteristics including involvement in the development of chimeric mice. The method actively promotes the clinical application and researches of the iPSCs, and provides new technical and theoretical bases for studying how to obtain and improve the iPSCs in people, pigs, cattle and other mammals.

The invention discloses a method for transfecting bovine somatic cells into inducted pluripotent stem cells (iPSCs) by adopting transcription factors, concretely comprising the following steps: 1) isolation and culture of bovine dermal fibroblasts; 2) cloning of bovine transcription factors maintaining pluripotent genes and construction of retroviral vectors of the transcription factors; 3) retrovirus packaging and preparation; and 4) infection of bovine dermal fibroblasts by retrovirus and acquisition of bovine inducted pluripotent stem cells. The invention first adopts the acellular human amniotic membranes as support to replace the mouse embryonic fibroblasts (MEFs) to maintain in vitro proliferation of the bovine iPSCs and keep the bovine iPSCs in undifferentiated pluripotent states for long time. The method which adopts gene inducing to generate the PSCs not only solves the technical problem that the PSCs of the animals such as cattle, sheep, pigs and other livestock are difficult to obtain but also avoids the problem of heterogeneous animal cell pollution caused by the feeder layer which applies the MEFs as the stem cells.

The invention relates to the field of preparation of urethral stents and discloses a method for culturing oral mucosa cells. The method comprises the following steps: separating oral mucosal epithelium and connective tissues of a rat by using digestive enzymes, and digesting by using pancreatin so as to remove the connective tissues, thereby obtaining the oral mucosa cells; inoculating the oral mucosa cells to mouse fibroblast cells 3T3 which are inactivated by mitomycin, and mixing keratinocyte serum-free culture solution KSFM and DMEM to form the mixed solution; and culturing the oral mucosa cells inoculated to the cells 3T3 by adopting the mixed solution. According to the method disclosed by the invention, the separation purity of the oral mucosa cells is improved, and the adherence and proliferation capacities of seed cells can be improved.

A method for isolating oogonial stem cells (OSCs) including forming an ovarian cell suspension from an ovary, forming ovaroids by culturing the ovarian cell suspension in a three-dimensional culture, and migrating the OSCs around the ovaroids by culturing the ovaroids on a mouse embryonic fibroblast (MEF)-coated plate.